Physician profile
Jeff Swanson
NPI 1326719857
$1,201.21
in general payments reported to CMS, 2019-2025
18 companies · $551 in 2025
The $551 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $15.04 · 2024: $485 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $212.44 | 2024-2025 | |
| Novo Nordisk INC | $157.64 | 2025 | Ozempic, Wegovy |
| Alkermes, INC. | $140.88 | 2025 | Lybalvi, Aristada |
| Si-Bone, INC. | $133.23 | 2022 | |
| Amgen INC. | $125.98 | 2024 | Otezla |
| Alnylam Pharmaceuticals INC. | $100.57 | 2024 | Givlaari |
| Lilly USA, LLC | $61.20 | 2022-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $41.02 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $33.06 | 2025 | Airsupra |
| Paratek Pharmaceuticals, INC. | $32.38 | 2025 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $28.32 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $24.00 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $20.11 | 2025 | Zoryve |
| Stryker Corporation | $20.02 | 2025 | Flowtriever |
| Glaxosmithkline, LLC. | $18.79 | 2024 | Arexvy, Trelegy Ellipta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.35 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $17.27 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.95 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.